We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01069913
First Posted: February 17, 2010
Last Update Posted: February 17, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Biogen
  Purpose
The purpose of this study is to measure two different formulations of BG00012 to determine how much of each formulation of BG00012 reaches the blood stream and how long it takes the body to get rid of it, when given as a single dose.

Condition Intervention Phase
Healthy Drug: BG00012 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Pharmacokinetics Profile Determination of BG00012 Standard Formulation and the BG00012 Active Pharmaceutical Ingredient (API) After a Single Oral Dose Administered to Healthy Male Volunteers

Resource links provided by NLM:


Further study details as provided by Biogen:

Primary Outcome Measures:
  • PK profiles of the current BG00012 standard formulation and the BG00012 API formulation in healthy volunteers. Primary PK parameter will be the area under the plasma concentration curve [ Time Frame: 4 days post dosing period 2 ]

Secondary Outcome Measures:
  • To assess the safety and tolerability of the current oral BG00012 standard formulation and the encapsulated oral BG00012 API [ Time Frame: 4 days after dosing period 2 ]

Enrollment: 14
Study Start Date: October 2009
Study Completion Date: January 2010
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: BG00012
BG00012 Standard Formulation
Drug: BG00012

Sequence 1: Oral 240 mg BG00012 Standard Formulation & Following 7 day washout period, 240 mg BG00012 API.

Sequence 2: 240 mg BG00012 API & Following 7 day washout period, 240 mg BG00012 Standard Formulation.

Active Comparator: BG00012 API
BG00012 API
Drug: BG00012

Sequence 1: Oral 240 mg BG00012 Standard Formulation & Following 7 day washout period, 240 mg BG00012 API.

Sequence 2: 240 mg BG00012 API & Following 7 day washout period, 240 mg BG00012 Standard Formulation.


  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males 18 to 55 years old, inclusive, at the time of informed consent.
  2. Must weigh between 50 kg and 110 kg, inclusive.
  3. Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive.
  4. All subjects must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.
  5. Must be a non-smoker, and no use of chewing tobacco, for at least 6 months prior to Day -1.
  6. Must have a screening physical examination and ECG without any clinically significant abnormality (as determined by the Investigator).

Exclusion Criteria:

  1. History of malignancy (subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible).
  2. History of severe allergic or anaphylactic reaction.
  3. History of any clinically significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major diseases, as determined by the Investigator.
  4. Clinically significant abnormal hematology or blood chemistry values, as determined by the Investigator.
  5. Serious infection (e.g., pneumonia, septicemia) within the 2 months prior to Day -1.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01069913


Sponsors and Collaborators
Biogen
Investigators
Study Director: Biogen Idec Medical Director Biogen Idec, Cambridge, MA USA
  More Information

Responsible Party: Biogen Idec, Medical Director
ClinicalTrials.gov Identifier: NCT01069913     History of Changes
Other Study ID Numbers: 109HV105
First Submitted: February 12, 2010
First Posted: February 17, 2010
Last Update Posted: February 17, 2010
Last Verified: February 2010

Keywords provided by Biogen:
Healthy Volunteer

Additional relevant MeSH terms:
Dimethyl Fumarate
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs